Advertisement

Inner Ear Infections (Labyrinthitis)

  • Nicholas A. Dewyer
  • Ruwan Kiringoda
  • Michael J. McKenna
Chapter

Abstract

Infection of the inner ear, or labyrinthitis, can be caused by a variety of pathogens. The diagnosis is usually made based on the clinical findings of sensorineural hearing loss and/or vertigo in the setting of an ongoing infection, particularly otitis media or meningitis. It should be determined whether the causative agent is bacterial or viral so that appropriate treatment may be administered. The inner ear is exquisitely sensitive to insults such as infection, and in many cases the patient is left with permanent sensorineural hearing loss and vestibular dysfunction following an inner ear infection. Acute suppurative labyrinthitis can progress to intracranial infectious complications and requires prompt treatment.

Keywords

Labyrinthitis Inner ear Infection Ear Diagnosis Treatment Viral Bacterial Facial paralysis 

References

  1. 1.
    Cook RD, Postma DS, Brinson GM, Prazma J, Pillsbury HC. Cytotoxic changes in hair cells secondary to pneumococcal middle-ear infection. J Otolaryngol. 1999;28(6):325–31.PubMedGoogle Scholar
  2. 2.
    Ichimiya I, Suzuki M, Hirano T, Mogi G. The influence of pneumococcal otitis media on the cochlear lateral wall. Hear Res. 1999;131(1-2):128–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Kawauchi H, DeMaria TF, Lim DJ. Endotoxin permeability through the round window. Acta Otolaryngol Suppl. 1989;457:100–15.PubMedGoogle Scholar
  4. 4.
    Tsuprun V, Cureoglu S, Schachern PA, Ferrieri P, Briles DE, Paparella MM, et al. Role of pneumococcal proteins in sensorineural hearing loss due to otitis media. Otol Neurotol. 2008;29(8):1056–60.CrossRefPubMedGoogle Scholar
  5. 5.
    Engel F, Blatz R, Schliebs R, Palmer M, Bhakdi S. Bacterial cytolysin perturbs round window membrane permeability barrier in vivo: possible cause of sensorineural hearing loss in acute otitis media. Infect Immun. 1998;66(1):343–6.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Kangsanarak J, Fooanant S, Ruckphaopunt K, Navacharoen N, Teotrakul S. Extracranial and intracranial complications of suppurative otitis media. Report of 102 cases. J Laryngol Otol. 1993;107(11):999–1004.CrossRefPubMedGoogle Scholar
  7. 7.
    Rosenfeld RM, Kay D. Natural history of untreated otitis media. Laryngoscope. 2003;113(10):1645–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;(9):CD004405.Google Scholar
  9. 9.
    Hartnick CJ, Kim HH, Chute PM, Parisier SC. Preventing labyrinthitis ossificans: the role of steroids. Arch Otolaryngol Head Neck Surg. 2001;127(2):180–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Philippon D, Bergeron F, Ferron P, Bussieres R. Cochlear implantation in postmeningitic deafness. Otol Neurotol. 2010;31(1):83–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. J Infect. 2016;73(1):18–27.CrossRefPubMedGoogle Scholar
  12. 12.
    Merchant SN, Gopen Q. A human temporal bone study of acute bacterial meningogenic labyrinthitis. Am J Otol. 1996;17(3):375–85.PubMedGoogle Scholar
  13. 13.
    Devriese PP. Facial paralysis in cephalic herpes zoster. Ann Otol Rhinol Laryngol. 1968;77(6):1101–19.CrossRefPubMedGoogle Scholar
  14. 14.
    Coulson S, Croxson GR, Adams R, Oey V. Prognostic factors in herpes zoster oticus (ramsay hunt syndrome). Otol Neurotol. 2011;32(6):1025–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Devriese PP, Moesker WH. The natural history of facial paralysis in herpes zoster. Clin Otolaryngol Allied Sci. 1988;13(4):289–98.CrossRefPubMedGoogle Scholar
  16. 16.
    Robillard RB, Hilsinger RL Jr, Adour KK. Ramsay Hunt facial paralysis: clinical analyses of 185 patients. Otolaryngol Head Neck Surg. 1986;95(3 Pt 1):292–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Nadol JBJ, Infections L. In: Merchant SN, Nadol JBJ, editors. Schuknecht’s pathology of the ear. 3rd ed. Beijing: People’s Medical Publishing House; 2010. p. 309.Google Scholar
  18. 18.
    Al-Hussaini A, Latif F, Berry S. Ear pain, vesicular rash, and facial palsy. BMJ. 2014;349:g7572.CrossRefPubMedGoogle Scholar
  19. 19.
    Goderis J, De Leenheer E, Smets K, Van Hoecke H, Keymeulen A, Dhooge I. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014;134(5):972–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Duval M, Park AH. Congenital cytomegalovirus: what the otolaryngologist should know. Curr Opin Otolaryngol Head Neck Surg. 2014;22(6):495–500.CrossRefPubMedGoogle Scholar
  21. 21.
    Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? J Pediatr. 1999;135(1):60–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Harris JP, Fan JT, Keithley EM. Immunologic responses in experimental cytomegalovirus labyrinthitis. Am J Otolaryngol. 1990;11(5):304–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011;364(22):2111–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010;303(14):1375–82.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143(1):16–25.CrossRefGoogle Scholar
  26. 26.
    Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933–43.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Centers for Disease Control and Prevention (CDC). Measles. Available at: http://www.cdc.gov/measles/hcp/index.html. Accessed October 2017.Google Scholar
  28. 28.
    Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol. 2006;208(2):199–214.CrossRefPubMedGoogle Scholar
  29. 29.
    Arnold W, Niedermeyer HP, Lehn N, Neubert W, Hofler H. Measles virus in otosclerosis and the specific immune response of the inner ear. Acta Otolaryngol. 1996;116(5):705–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Karosi T, Konya J, Szabo LZ, Sziklai I. Measles virus prevalence in otosclerotic stapes footplate samples. Otol Neurotol. 2004;25(4):451–6.CrossRefPubMedGoogle Scholar
  31. 31.
    McKenna MJ, Mills BG, Galey FR, Linthicum FH Jr. Filamentous structures morphologically similar to viral nucleocapsids in otosclerotic lesions in two patients. Am J Otol. 1986;7(1):25–8.PubMedGoogle Scholar
  32. 32.
    McKenna MJ, Mills BG. Immunohistochemical evidence of measles virus antigens in active otosclerosis. Otolaryngol Head Neck Surg. 1989;101(4):415–21.CrossRefPubMedGoogle Scholar
  33. 33.
    McKenna MJ, Mills BG. Ultrastructural and immunohistochemical evidence of measles virus in active otosclerosis. Acta Otolaryngol Suppl. 1990;470:130–9. discussion 139–40.PubMedGoogle Scholar
  34. 34.
    McKenna MJ, Kristiansen AG, Haines J. Polymerase chain reaction amplification of a measles virus sequence from human temporal bone sections with active otosclerosis. Am J Otol. 1996;17(6):827–30.PubMedGoogle Scholar
  35. 35.
    Niedermeyer H, Arnold W, Neubert WJ, Hofler H. Evidence of measles virus RNA in otosclerotic tissue. ORL J Otorhinolaryngol Relat Spec. 1994;56(3):130–2.CrossRefPubMedGoogle Scholar
  36. 36.
    Niedermeyer HP, Arnold W. Otosclerosis: a measles virus associated inflammatory disease. Acta Otolaryngol. 1995;115(2):300–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Niedermeyer HP, Arnold W, Schuster M, Baumann C, Kramer J, Neubert WJ, et al. Persistent measles virus infection and otosclerosis. Ann Otol Rhinol Laryngol. 2001;110(10):897–903.CrossRefPubMedGoogle Scholar
  38. 38.
    Bordley JE. Editorial. The effect of viral infection on hearing. A state-of-the-art report with special emphasis on congenital rubella. Arch Otolaryngol. 1973;98(4):217.CrossRefPubMedGoogle Scholar
  39. 39.
    Hardy JB. Fetal consequences of maternal viral infections in pregnancy. Arch Otolaryngol. 1973;98(4):218–27.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. Clin Microbiol Rev. 2000;13(4):571–87.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Barr B, Lundstrom R. Deafness following maternal rubella. Retrospective and prospective studies. Acta Otolaryngol. 1961;53:413–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Burgess RC, Michaels L, Bale JF Jr, Smith RJ. Polymerase chain reaction amplification of herpes simplex viral DNA from the geniculate ganglion of a patient with Bell’s palsy. Ann Otol Rhinol Laryngol. 1994;103(10):775–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Furuta Y, Fukuda S, Chida E, Takasu T, Ohtani F, Inuyama Y, et al. Reactivation of herpes simplex virus type 1 in patients with Bell’s palsy. J Med Virol. 1998;54(3):162–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;124(1 Pt 1):27–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck Surg. 2013;149(3 Suppl):S1–27.CrossRefPubMedGoogle Scholar
  46. 46.
    Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med. 2007;357:1598–607.CrossRefPubMedGoogle Scholar
  47. 47.
    Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F, et al. Antiviral treatment for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2015;(11):CD001869.Google Scholar
  48. 48.
    Smouha E, Toh E, Schaitkin BM. Surgical treatment of Bell’s palsy: current attitudes. Laryngoscope. 2011;121(9):1965–70.PubMedGoogle Scholar
  49. 49.
    Gantz BJ, Rubinstein JT, Gidley P, Woodworth GG. Surgical management of Bell’s palsy. Laryngoscope. 1999;109(8):1177–88.CrossRefPubMedGoogle Scholar
  50. 50.
    Cannon RB, Gurgel RK, Warren FM, Shelton C. Facial nerve outcomes after middle fossa decompression for Bell’s palsy. Otol Neurotol. 2015;36(3):513–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Diehl GE, Holtmann S. Lyme borreliosis and its significance for the ENT physician. Laryngorhinootologie. 1989;68(2):81–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Bradshaw D, Pallawela S, Nelson M, Scott C, Day S. Otosyphilis: missed opportunities for early treatment? Sex Transm Infect. 2012;88(8):573.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Otology and LaryngologyHarvard Medical SchoolBostonUSA
  2. 2.Department of OtolaryngologyMassachusetts Eye and Ear/Massachusetts General HospitalBostonUSA
  3. 3.Palo Alto Medical FoundationPalo AltoUSA

Personalised recommendations